论文部分内容阅读
目的观察培菲康在治疗幽门螺杆菌感染慢性胃炎中的作用。方法 240例慢性胃炎患者随机分为两组,治疗组(120例):雷贝拉唑10mgbid+阿莫西林1.0bid+左氧氟沙星0.2gbid,疗程7d;培菲康2粒tid(d8～d21)。对照组(120例):雷贝拉唑10mgbid+阿莫西林1.0gbid+左氧氟沙星0.2gbid,疗程7d(d1～d7)。患者停药后4周进行13C尿素呼气试验,阴性者判断为幽门螺杆菌根除,观察两组幽门螺杆菌根除率和不良反应。结果治疗组根除率为85.83%,对照组为71.67%(P<0.05),不良反应治疗组发生率为21.67%,对照组为26.67%,两组差异无统计学意义(P>0.05)。结论慢性胃炎患者在抗幽门螺杆菌治疗中加用培菲康可提高幽门螺杆菌根除率。
Objective To observe the effect of Peifeikang in the treatment of Helicobacter pylori infection in chronic gastritis. Methods A total of 240 patients with chronic gastritis were randomly divided into two groups: treatment group (120 cases): rabeprazole 10mgbid + amoxicillin 1.0bid + levofloxacin 0.2gbid for 7 days, and Pefikan 2 tablets tid (d8 ~ d21). Control group (120 cases): rabeprazole 10mgbid + amoxicillin 1.0gbid + levofloxacin 0.2gbid, treatment 7d (d1 ~ d7). Four weeks after discontinuation of the drug, 13C urea breath test was performed in the patients, and H. pylori eradication was judged as negative. The eradication rate and adverse reactions of H. pylori in both groups were observed. Results The eradication rate was 85.83% in the treatment group and 71.67% in the control group (P <0.05). The incidence of adverse reactions was 21.67% in the treatment group and 26.67% in the control group. There was no significant difference between the two groups (P> 0.05). Conclusion The treatment of chronic gastritis in patients with Helicobacter pylori with Peifei Kang can improve H. pylori eradication rate.